FDA Approves Wegovy HD, a Higher-Dose Option for GLP-1 Patients
NewBeauty Facebook Pinterest Instagram Youtube find a doctor Face Adult Acne Antioxidants Anti-Aging Celebrity Chronic Skin Conditions Eye Hydration Hyperpigmentation Makeup View All Eyebrows Eye Color Foundation Fragrance Lip Color Makeovers Male Skin Care Peels Pre-Event Prep Retinoids Sensitive Skin Skin Care Skin Health Smile Sun Care Treatments Fillers Microneedling Post-Procedure Skin Care Neurotoxins Regenerative Aesthetics Skin Lifting Body Body Sculpting Breasts Butts Cellulite Hair Removal Hands + Nails Legs Pregnancy Find a Doctor Hair Bond Repair Celebrity Dry Hair Frizzy Hair Gray Hair Hair Color Hair Growth Hair Repair Scalp Health Styling + Tips Awards NB100 Awards 15th Annual Beauty Awards 2025 NewBeauty Readers’ Choice Awards Shopping Gift Guides Product Reviews NewBeauty Storefront Wellness Fitness GLP-1s Health Menopause About Us TESTTUBE Search for: Search HomeWellnessGLP-1s FDA Approves Wegovy HD, a Higher-Dose Option for GLP-1 Patients A closer look at the new dose and who it’s intended for. Tatiana Bido Published: Mar 24, 2026 Getty Images GLP-1 weight loss is not slowing down. Wegovy’s maker, Novo Nordisk, has received FDA approval for a higher-dose version of the injectable, signaling a new phase in how far these treatments can go. In clinical trials, patients using the higher-dose formulation saw average weight loss of around 20 percent or more, with some individuals reaching even higher numbers (up to 25 percent in some) that continue to shift expectations around what’s possible with medical weight loss. “We are excited to bring Wegovy HD to adults with obesity who are looking for powerful weight loss,” said Jamey Millar, executive vice president of U.S. operations at Novo Nordisk, in a press release.